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1. Overview
Cardiovascular disease is a leading cause of morbidity and
mortality with considerable financial impact worldwide.
This special issue explores recent developments and novel
strategies to target emerging risk factors central to the
complex molecular mechanisms regulating the cardiovas-
cular disease process. The concept was prompted by dis-
cussions arising from the UCL-Royal Free International
Cardiovascular Diseases Workshops held each year at the
Royal Free Hospital campus of University College London in
collaboration with the University of Bern, Switzerland. These
annual international workshops provide an integrated forum
for clinicians and scientists involved in multidisciplinary
studies in cardiovascular medicine to discuss recent advances
aimed at integrating the latest findings in basic researchmore
quickly and efficiently into medical practice.
The causes of cardiovascular disease are numerous but
emerging areas of therapeutic interest are equally diverse and
include novel molecular mechanisms by which cardiovas-
cular risk factors and mediators, including reactive oxygen
species and scavenger receptors, interact to regulate vascular
cell proliferation and extra cellular matrix remodeling that
play important roles during angiogenesis and cell response
to injury and ischemia.
The scavenger receptor LOX-1, for example, mediates
OxLDL endocytosis via a clathrin-independent internaliza-
tion pathway. Administration of LOX-1 antibodies in cellular
and animal models suggests that such intervention inhibits
atherosclerosis. Anti-atherogenic strategies that target LOX-
1 function using gene therapy or small molecule inhibitors
would be new ways to address the increasing incidence of
vascular disease.
The role of special inflammatory molecules in the
initiation and promotion of vascular inflammation is also
under investigation. In particular the link between sterile
inflammation, ischemia, and the innate immune system is
providing important new information concerning the role
of specific Toll-like receptors and endogenous molecules
released in response to tissue injury. As sentinels of innate
immunity TLRs are molecular pattern recognition receptors
that recognize exogenous as well as tissue-derived molec-
ular danger signals that promote chronic inflammation
[1, 2]. Interestingly, these endogenously derived “danger”
molecules appear to activate and induce differential TLR
dimerisation compared to exogenously derived bacterial
or viral components. Consequently modulation of TLR
signaling by specific TLR agonists or antagonists, alone
or in combination, may, therefore, be a novel therapeu-
tic approach to treat various cardiovascular inflammatory
conditions such as atherosclerosis, secondary microvascular
complications of diabetes, and peripheral arterial disease
(PAD) without compromising the normal immune response.
Additional signaling pathways and novel strategies
that may prevent or slow the development of trans-
plant arteriopathy and post ischemic reperfusion injurys
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are likewise now beginning to be defined. Mechanisms
by which haemodynamic forces such as pressure, stretch,
and fluid shear stress are sensed by cells within the
cardiovascular system are helping in the understanding
of the atheroprotective benefits of steady laminar blood
flow.
Here, there is also evidence that nitric oxide (NO)
and its endogenous inhibitor asymmetric dimethylarginine
(ADMA) play significant roles. Recent experimental work
implicates the ADMA-NO pathway and highlights the
potential of manipulating this as a novel adjunct therapy.
Related, mechanisms may be at play in relation to the
damaging effects of oxidative stress on the development
of enhanced fibroblast activity resulting in fibrosis of the
skin, heart, and lungs, vascular dysfunction and ultimately
internal organ failure, and death in scleroderma. Research
suggests that the free radical nitric oxide (NO), a key
mediator of oxidative stress, can profoundly influence the
early microvasculopathy, and possibly the ensuing fibrogenic
response. Recently, animal models and human studies have
also identified dietary antioxidants, such as epigallocatechin-
3-gallate (EGCG), which function as a protective system
against oxidative stress and fibrosis. Hence, targeting EGCG
may prove a possible candidate for therapeutic treatment
aimed at reducing both oxidant stress and the fibrotic effects
associated with scleroderma.
Manipulation of cyclic GMP and cyclic AMP is a further
emerging target for intervention in cardiovascular diseases
such as hypertension, atherosclerosis, and heart failure.
Drugs that enable the manipulation of these systems repre-
sent an exciting new area of pharmaceutical development.
Basic research has also identified a number of novel inter-
ventions that stimulate innate resistance of tissues to
ischemia-reperfusion injury that may have important impli-
cations in the management of stroke and myocardial
infarction. In particular, clinical trial data underpin one of
these “conditioning” strategies, the phenomenon of remote
ischemic preconditioning. This may in particular provide a
novel cardioprotective strategy for the diabetic heart which
evidence suggests may be more susceptible to ischemic
reperfusion injury.
Additionally, the study of connexins (Cxs) and cell-
to-cell interactions via gap junctional communication is
becoming an active area of investigation. Changes in Cxs
found in diabetes are associated with both direct effects
within the vasculature and indirect effects, by impairment of
homeostasis in vital organs such as liver and kidney. Recent
data suggests that Cxs targeting may alleviate some of the
symptoms of microvascular complications, as demonstrated
in recent work using topical Cx43 AsODN (antisense
oligodeoxynucleotide) gel treatment. Cxs may also be used as
future predictors of both diabetes progression and severity.
Similarly, erythropoietin (EPO) has tissue-protective
properties, but increases the risk of thromboembolism
by raising haemoglobin concentration. New generation
EPO derivatives, however, are tissue protective with-
out the haematopoietic side effects and preclinical stud-
ies have demonstrated their potential effectiveness and
safety.
Cytokine targeting may also play a future role in the ther-
apy of peripheral vascular disease, in particular chemokine
stromal-cell-derived factor-1 (SDF-1 aka CXCL12). Biologi-
cal effects of SDF-1 are mediated by the chemokine receptor
CXCR4, a 352-amino-acid rhodopsin-like transmembrane-
specific G protein-coupled receptor (GPCR). There is evi-
dence that the administration of SDF-1 increases blood flow
and perfusion via recruitment of endothelial progenitor cells
(EPCs).
As more becomes known, molecular genomic approach-
es are increasingly being used. MicroRNAs (miRNAs) are
endogenous, small, noncoding RNAs that negatively control
gene expression of target mRNAs. This phenomenon may
be of benefit in regulating post-ischemic angiogenesis and
vascular repair and analysis of circulating miRNAs may
potentially be useful as potential biomarkers in ischemic
diseases. Targeted in situ gene correction is currently being
explored as a means to modulate Apolipoprotein E (ApoE)
gene activity. APOE, a 34-kDa circulating glycoprotein,
has pleiotropic anti-atherogenic functions and hence is a
candidate to treat hypercholesterolaemia and atheroscle-
rosis. In particular, we have the possibility and potential
benefit of combining two technological advances to repair
aberrant APOE genes: (i) an engineered endonuclease to
introduce a double-strand break in exon 4, which con-
tains the common, but dysfunctional, ε2 and ε4 alleles;
(ii) an efficient and selectable template for homologous
recombination (HR) repair, namely, an adeno-associated
viral (AAV) vector, which harbors the wild-type APOE
sequence. This technology is currently applicable ex vivo, for
example, to target haematopoietic or induced pluripotent
stem cells, and also for in vivo organ gene targeting.
It is to be hoped that such emerging technology will
eventually translate into patient therapy to reduce CVD
risk.
Other genome-wide association studies (GWAS) have
revolutionized research into genetic variants that under-
pin the development of many complex diseases including
abdominal aortic aneurysm and allowed the exploration of
mechanisms by which identified loci may contribute to its
development. Studies have also highlighted the potential of
post-GWAS analytical strategies to improve our understand-
ing of the disease further.
Finally, progress in the identification of key mechanisms
regulating tissue repair, and the potential of stem cell therapy
and tissue engineering, offer promising new possibilities in
bypass grafting and recovery from cardiac injury.
We hope that readers will find that this special issue
addresses the important challenges, opportunities, and
recent developments that are currently being exploited in
cardiovascular research with the potential to promote the
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implementation of novel translational strategies for optimiz-
ing the care and treatment of patients with cardiovascular
disease.
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